Fulgent Genetics Inc
$
6.19
-0.21 (-3.27%)
| Volume: | 371 | Avg Vol (1m): | 11,556 |
| Market Cap $: | 113.44 Mil | Enterprise Value $: | 84.01 Mil |
| P/E (TTM): | 0.00 | P/B: | 2.28 |
| Earnings Power Value | 0 |
| Net Current Asset Value | 1.68 |
| Tangible Book | 2.74 |
| Projected FCF | 0 |
| Median P/S Value | 5.32 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 9.2/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt | N/A | |
| Equity-to-Asset | 0.90 |
Equity-to-Asset range over the past 10 years
Min: 0.76, Med: 0.94, Max: 0.96
Current: 0.9
| |
| Interest Coverage | No Debt | N/A | |
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 12.14 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -3.24 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -21.29 |
Operating Margin range over the past 10 years
Min: -77.46, Med: -23.75, Max: 5.02
Current: -21.29
| |
| Net Margin % | -25.40 |
Net Margin range over the past 10 years
Min: -335.13, Med: -29.26, Max: -13.4
Current: -25.4
| |
| ROE % | -10.81 |
ROE range over the past 10 years
Min: -254.33, Med: -45.84, Max: -4.62
Current: -10.81
| |
| ROA % | -10.18 |
ROA range over the past 10 years
Min: -209.1, Med: -16.74, Max: -4.36
Current: -10.18
| |
| ROC (Joel Greenblatt) % | -40.85 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -190.32, Med: -45.32, Max: 14.84
Current: -40.85
| |
| 3-Year Total Revenue Growth Rate | 30.60 |
3-Year Revenue Growth Rate range over the past 10 years
Min: 16.6, Med: 68, Max: 119.4
Current: 16.6
| |
| 3-Year Total EBITDA Growth Rate | 13.10 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: -16.9, Med: 2.8, Max: 22.5
Current: 22.5
| |
| 3-Year EPS w/o NRI Growth Rate | 0.70 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0.35, Max: 0.7
Current: 0.7
|
» FLGT's 30-Y Financials
Financials (Next Earnings Date: 2019-08-06)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:FLGT
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Medical Diagnostics & Research NAICS : 621511 SIC : 8071 |
| Compare | NAS:ITUS OSL:GENT-ME AMEX:VNRX NAS:MOTS ROCO:6598 ROCO:6615 XKRX:109820 XKRX:238120 LSE:AGL SGX:1B1 XPAR:CLNV BOM:524394 TPE:4155 ASX:VHT WAR:VOX TSE:3386 XKRX:084650 TSXV:PRN XTER:LIO1 ASX:CMP |
| Traded in other countries | 7F0.Germany |
| Address | 4978 Santa Anita Avenue, Temple City, CA, USA, 91780 |
| Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 2.28 |
PB Ratio range over the past 10 years
Min: 1.05, Med: 1.62, Max: 9.88
Current: 2.28
| |
| PS Ratio | 5.09 |
PS Ratio range over the past 10 years
Min: 2.7, Med: 4.36, Max: 11.19
Current: 5.09
| |
| Price-to-Operating-Cash-Flow | 67.26 |
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 15.16, Med: 40.61, Max: 74.46
Current: 67.26
| |
| EV-to-EBIT | -17.88 |
EV-to-EBIT range over the past 10 years
Min: -454.5, Med: -7.3, Max: 237.5
Current: -17.88
| |
| EV-to-EBITDA | -33.40 |
EV-to-EBITDA range over the past 10 years
Min: -37.9, Med: -9.8, Max: 104.4
Current: -33.4
| |
| EV-to-Revenue | 3.79 |
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 3, Max: 11.9
Current: 3.79
| |
| Current Ratio | 11.33 |
Current Ratio range over the past 10 years
Min: 1.63, Med: 10.58, Max: 18.2
Current: 11.33
| |
| Quick Ratio | 11.33 |
Quick Ratio range over the past 10 years
Min: 1.63, Med: 10.58, Max: 18.2
Current: 11.33
| |
| Days Sales Outstanding | 75.47 |
Days Sales Outstanding range over the past 10 years
Min: 75.47, Med: 87.16, Max: 110.53
Current: 75.47
| |
| Days Payable | 48.79 |
Days Payable range over the past 10 years
Min: 22.61, Med: 64.34, Max: 149.65
Current: 48.79
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -12.10 |
3-Year Share Buyback Rate range over the past 10 years
Min: -12.1, Med: -11.95, Max: -11.8
Current: -12.1
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.26 |
Price-to-Tangible-Book range over the past 10 years
Min: 1.12, Med: 1.56, Max: 9.33
Current: 2.26
| |
| Price-to-Median-PS-Value | 1.16 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.61, Med: 0.97, Max: 2.17
Current: 1.16
| |
| Earnings Yield (Joel Greenblatt) % | -5.61 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.1, Med: -6.6, Max: 2.1
Current: -5.61
|
More Statistics
| Revenue (TTM) (Mil) $ | 22.07 |
| EPS (TTM) $ | -0.24 |
| Beta | 0 |
| Volatility % | 53.52 |
| 52-Week Range $ | 3.02 - 7.85 |
| Shares Outstanding (Mil) | 18.32 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | N |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |